<div id="readability-page-1">09:26 AM EST, 01/05/2026 (MT Newswires) -- Health care stocks were lower premarket Monday, with the iShares Biotechnology ETF (IBB) slipping 0.3% and the State Street Health Care Select Sector SPDR ETF ( XLV ) down 0.5%.GH Research ( GHRS ) shares were up more than 38% after the company said the US Food and Drug Administration has lifted the clinical hold on its investigational new drug application for GH001 as a potential treatment for depression, allowing the company to proceed with subject enrollment in the US.Novo Nordisk ( NVO ) stock was up more than 2% after the company said it will offer its 1.5 mg and 4 mg oral weight loss drug Wegovy at $149 per month to self-paying patients in the US, starting Jan. 5.Gyre Therapeutics ( GYRE ) shares were nearly 6% higher after the company said its Chinese unit reached an agreement with China's Center for Drug Evaluation to seek conditional approval for its liver fibrosis treatment Hydronidone. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

GYRE

GHRS

诺和诺德公司

周一盘前，医疗保健类股票下跌，iShares 生物技术 ETF 下跌 0.3%，State Street 医疗保健精选行业 SPDR ETF 下跌 0.5%。GH Research 的股票在 FDA 解除其 GH001 药物申请的临床限制后飙升超过 38%。诺和诺德公司的股票上涨超过 2%，因其宣布 Wegovy 减肥药的月售价为 149 美元。Gyre Therapeutics 的股票在与中国达成肝纤维化治疗的有条件批准协议后上涨近 6%

板块更新：医疗保健类股在周一盘前下跌